Ticker > Company >

Vivo Bio Tech share price

Vivo Bio Tech Ltd.

BSE: 511509 SECTOR: Pharmaceuticals & Drugs  27.9 K   125   9

37.99
+1.56 (4.28%)
BSE: 08 Sep 04:01 PM

Price Summary

Today's High

₹ 38

Today's Low

₹ 35.56

52 Week High

₹ 56.9

52 Week Low

₹ 31.2

FinStar is Suspended!

The FinStar rating for this company is currently unavailable due to limited data disclosure. As a micro-cap company, it may carry higher risk and limited transparency. We will update the FinStar rating once more reliable data becomes available.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

81.04 Cr.

Enterprise Value

150.57 Cr.

No. of Shares

2.13 Cr.

P/E

9.25

P/B

0.89

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  42.68

CASH

1.32 Cr.

DEBT

70.84 Cr.

Promoter Holding

36.43 %

EPS (TTM)

₹  4.11

Sales Growth

-13.06%

ROE

4.78 %

ROCE

10.15%

Profit Growth

-4.24 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-13.06%
3 Year-4.65%
5 Year-4.27%

Profit Growth

1 Year-4.24%
3 Year-23.73%
5 Year2.31%

ROE%

1 Year4.78%
3 Year5.08%
5 Year9.09%

ROCE %

1 Year10.15%
3 Year10.32%
5 Year12.92%

Debt/Equity

1.3098

Price to Cash Flow

5.12

Interest Cover Ratio

1.5102

CFO/PAT (5 Yr. Avg.)

3.93430897826416

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 36.43 0.00
Mar 2025 40.85 0.00
Dec 2024 38.88 0.00
Sep 2024 42.08 0.00
Jun 2024 42.08 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The Company has been maintaining an effective average operating margins of 35.5741276986612% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of 69.7373 days.
  • The company has a good cash flow management; CFO/PAT stands at 3.93430897826416.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 45.7247901939207.

 Limitations

  • The company has shown a poor profit growth of -23.7270220463147% for the Past 3 years.
  • The company has shown a poor revenue growth of -4.65187129741923% for the Past 3 years.
  • Company has a poor ROE of 5.0820273700276% over the past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 10.13 12.04 12.21 12.29 12.42
Total Expenditure 5.76 6.37 6.6 7.15 6.89
Operating Profit 4.38 5.67 5.61 5.14 5.53
Other Income 0.01 4.63 0.01 0.15 0.14
Interest 1.92 2.06 1.84 1.68 1.5
Depreciation 2.23 2.29 2.25 2.25 2.64
Exceptional Items 0 0 0 0 0
Profit Before Tax 0.23 5.95 1.54 1.37 1.52
Tax 0.06 0.63 0.64 0.18 0.14
Profit After Tax 0.18 5.31 0.9 1.19 1.37
Adjusted EPS (Rs) 0.12 3.56 0.55 0.69 0.69

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 55.35 51.78 51.39 51.62 44.88
Total Expenditure 42.88 33.97 35.3 29.8 23.63
Operating Profit 12.47 17.81 16.09 21.82 21.25
Other Income 0.05 0.08 0.09 0.04 0.04
Interest 3.1 3.67 4.27 7.99 7.95
Depreciation 5.17 5.59 7.44 9.27 9.29
Exceptional Items 0 0 0 0 0
Profit Before Tax 4.26 8.62 4.47 4.61 4.05
Tax -0.19 2.94 2.27 1.97 1.53
Net Profit 4.44 5.68 2.2 2.63 2.52
Adjusted EPS (Rs.) 3.45 4.24 1.54 1.77 1.69

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 12.89 13.42 14.26 14.9 14.9
Total Reserves 20.15 29.12 32.88 36.97 39.49
Borrowings 7.41 12.42 47.88 40.87 39.56
Other N/C liabilities -1.13 0.51 2.1 3.1 3.03
Current liabilities 20.56 21.83 23.18 24.97 37.81
Total Liabilities 59.87 77.31 120.3 120.81 134.8
Assets
Net Block 31.63 48.69 91.81 85.51 77.01
Capital WIP 0.15 0.32 0.87 1.9 9.21
Intangible WIP 0 0 0 0 0
Investments 0.04 0.04 0.04 0.04 0.04
Loans & Advances 0 0 0 0 0
Other N/C Assets 0.06 0.05 0.4 0.47 0.32
Current Assets 27.99 28.21 27.18 32.88 48.22
Total Assets 59.87 77.31 120.3 120.81 134.8
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 4.26 8.62 4.47 4.61 4.05
Adjustment 8.27 9.12 11.43 16.92 17.07
Changes in Assets & Liabilities -1.9 2.82 3.98 -3.46 -2.24
Tax Paid 0.19 -2.94 -2.27 -1.97 -1.53
Operating Cash Flow 7.72 14.1 16.43 14.73 15.83
Investing Cash Flow -7.08 -22.82 -51.11 -4 -7.95
Financing Cash Flow -0.18 8.83 35.04 -11.2 -7.56
Net Cash Flow 0.46 0.11 0.37 -0.47 0.32

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 42.08 42.08 38.88 40.85 36.43
cryptologic systems priva... 9.02 9.02 8.34 7.84 6.30
iragavarapu constructions... 6.71 6.71 6.20 5.83 4.69
iron age india ltd 4.03 4.03 3.72 3.50 2.81
kompella modini - - - 1.30 1.05
kompella ramakrishna para... - - - 0.49 3.20
kompella viswanath 1.01 1.01 0.93 4.37 3.52
lopa mudra kompella - - - 0.49 1.14
maxcell phones communicat... 8.05 8.05 7.44 6.99 5.63
pki solutions private lim... 4.03 4.03 3.72 3.50 2.81
shri shri resorts pvt ltd... 7.16 7.16 6.62 - 5.00
toomuluru sitamma 0.40 0.40 0.37 0.35 0.28
shri shri resorts private... - - - 6.22 -
kompella madhavi latha 1.68 1.68 1.55 - -
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 57.92 57.92 61.12 59.15 63.57
anil kumar pinapala 1.74 1.74 - 1.51 1.22
antique infotech private ... - - - 1.73 12.19
dwight technologies priva... - - - - 5.18
elite class asset holding... 8.72 8.72 8.06 7.57 6.09
every wear import and exp... 4.39 4.39 3.89 2.18 2.32
mallemkonda realities pvt... 5.89 - 5.44 5.11 1.67
rite equity sdn bhd 3.77 3.77 3.48 3.27 -
sridhar yadav indur - - 1.24 1.00 -
anil pinapala - - 1.61 - -
jyothika vanamali - - 1.24 - -
kannan nadar - - 1.24 - -
mallemkonda realities pvt... - 5.89 - - -
vean smart infra private ... 3.35 2.74 - - -

Annual Reports

Title Link
Title Link
Annual Report 2021
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation related to this company.Report us

Company News

Vivo Bio Tech informs about updates 20 Aug, 5:37 PM Vivo Bio Tech secures pre-clinical testing contract worth Rs 10.75 crore 20 Aug, 12:13 PM Vivo Bio Tech - Quaterly Results 12 Aug, 7:52 PM Vivo Bio Tech - Quaterly Results 12 Aug, 7:52 PM Vivo Bio Tech informs about press release 4 Jul, 2:12 PM Vivo Bio Tech submits notice of postal ballot 3 Jul, 1:07 PM Vivo Bio Tech informs about change in management 30 Jun, 2:55 PM Vivo Bio Tech informs about newspaper publication 21 May, 4:35 PM Vivo Bio Tech - Quaterly Results 19 May, 8:37 PM Vivo Bio Tech - Quaterly Results 19 May, 8:37 PM Vivo Bio Tech informs about closure of trading window 27 Mar, 5:03 PM Vivo Bio Tech informs about disclosure 7 Mar, 11:27 AM Vivo Bio Tech informs about disclosure 7 Mar, 11:19 AM Vivo Bio Tech informs about disclosure 20 Feb, 2:40 PM Vivo Bio Tech launches large animal facility 13 Jan, 12:41 PM Vivo Bio Tech informs about launch of large animal facility 13 Jan, 12:05 PM Vivo Bio Tech - Quaterly Results 9 Jan, 6:33 PM Vivo Bio Tech - Quaterly Results 9 Jan, 6:33 PM Vivo Bio Tech - Quaterly Results 9 Jan, 6:33 PM Vivo Bio Tech informs about postal ballot notice 5 Dec, 2:46 PM Vivo Bio Tech informs about newspaper advertisement 16 Nov, 3:56 PM Vivo Bio Tech informs about newspaper publication 27 Aug, 12:37 PM Vivo Bio Tech - Quaterly Results 10 Aug, 5:27 PM Vivo Bio Tech - Quaterly Results 10 Aug, 5:27 PM Vivo Bio Tech - Quaterly Results 10 Aug, 5:27 PM Vivo Bio Tech informs about press release 20 Jun, 3:02 PM Vivo Bio Tech informs about notice of postal ballot 19 Jun, 2:16 PM Vivo Bio Tech - Quaterly Results 20 May, 7:49 PM Vivo Bio Tech - Quaterly Results 20 May, 7:49 PM Vivo Bio Tech informs about loss of share certificate 20 Apr, 4:30 PM Vivo Bio Tech informs about loss of share certificates 4 Mar, 5:00 PM Vivo Bio Tech - Quaterly Results 12 Feb, 7:38 PM Vivo Bio Tech - Quaterly Results 12 Feb, 7:38 PM Vivo Bio Tech - Quaterly Results 7 Aug, 8:14 PM Vivo Bio Tech - Quaterly Results 7 Aug, 8:14 PM Vivo Bio Tech informs about compliances certificate 10 Jul, 2:35 PM Vivo Bio Tech - Quaterly Results 10 Aug, 8:13 PM Vivo Bio Tech to purchase land and building in Telangana 28 Feb, 4:55 PM Vivo Bio Tech informs about disclosure 10 Feb, 10:01 AM Vivo Bio Tech - Quaterly Results 2 Feb, 8:01 PM Vivo Bio Tech - Quaterly Results 2 Feb, 8:01 PM Vivo Bio Tech executes lease deed with Andhra Pradesh Med Tech Zone 31 Jan, 9:18 AM Vivo Bio Tech informs about postal ballot notice 7 Dec, 11:50 AM Vivo Bio Tech gets contract from Biological E 30 Aug, 9:11 AM Vivo Bio Tech informs about clarification 15 Jun, 2:27 PM Vivo Bio Tech informs about clarification on price movement 7 May, 1:34 PM Vivo Bio Tech submits disclosure 26 Apr, 5:02 PM Vivo Bio Tech informs about disclosure 17 Nov, 10:24 AM Vivo Bio Tech - Quaterly Results 28 Aug, 7:53 PM

Vivo Bio Tech Stock Price Analysis and Quick Research Report. Is Vivo Bio Tech an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Vivo Bio Tech. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Vivo Bio Tech has a PE ratio of 9.24758404128429 which is low and comparatively undervalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Vivo Bio Tech has ROA of 1.9736% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Vivo Bio Tech has a Current ratio of 1.2753.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Vivo Bio Tech has a ROE of 4.7824%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Vivo Bio Tech has a Debt to Equity ratio of 1.3098 which means that the company has low proportion of debt in its capital.

  • Sales growth: Vivo Bio Tech has reported revenue growth of -13.0594% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Vivo Bio Tech for the current financial year is 47.3568699100946%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Vivo Bio Tech is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Vivo Bio Tech is Rs 4.1081. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Vivo Bio Tech in Ticker for free. Also, one can get the intrinsic value of Vivo Bio Tech by using Valuation Calculators, which are available with a Finology ONE subscription. 

Vivo Bio Tech FAQs

Q1. What is Vivo Bio Tech share price today?
Ans: The current share price of Vivo Bio Tech is Rs 37.99.

Q2. What is the market capitalisation of Vivo Bio Tech?
Ans: Vivo Bio Tech has a market capitalisation of Rs 81.044906579 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Vivo Bio Tech?
Ans: The PE ratio of Vivo Bio Tech is 9.24758404128429 and the P/B ratio of Vivo Bio Tech is 0.890127063939662, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Vivo Bio Tech share?
Ans: The 52-week high share price of Vivo Bio Tech is Rs 56.9, and the 52-week low share price of Vivo Bio Tech is Rs 31.2.

Q5. Does Vivo Bio Tech pay dividends?
Ans: Currently, Vivo Bio Tech does not pay dividends. Dividend yield of Vivo Bio Tech is around 0%.

Q6. What are the face value and book value of Vivo Bio Tech shares?
Ans: The face value of Vivo Bio Tech shares is Rs 10, while the book value per share of Vivo Bio Tech is around Rs 42.6793. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Vivo Bio Tech?
Ans: Vivo Bio Tech has a total debt of Rs 70.8374 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Vivo Bio Tech?
Ans: The ROE of Vivo Bio Tech is 4.7824% and ROCE of Vivo Bio Tech is 10.1501%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Vivo Bio Tech a good buy for the long term?
Ans: The Vivo Bio Tech long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Vivo Bio Tech undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Vivo Bio Tech appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Vivo Bio Tech’s financials?
Ans: You can review Vivo Bio Tech’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Vivo Bio Tech
X